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PRESCRIPTION DRUG IMPORTATION: AN
EXPANDED FDA PERSONAL USE
EXEMPTION AND QUALIFIED REGULATORS
FOR FOREIGN-PRODUCED
PHARMACEUTICALS
Elliott A. Foote

∗

ABSTRACT

H

igh-priced prescription drugs have been a problem for U.S.
consumers. The United States market economy coupled with
patent protection for these products creates an incentive for
pharmaceutical companies to charge as much as possible. Unable to
afford these drugs, many people are reaching out to neighboring
countries and abroad to seek lower-cost options. It has also created a
market for online mail-order pharmaceuticals. Despite the need for
these drugs, the Food and Drug Administration (“FDA”) continues to
make importation illegal.
In formulating its policy, the FDA cites to safety and
innovation concerns. Claimed uncertainty about the source of foreign
prescription drugs has led to ineffective federal policy in this area. To
date, none of the major amendments to the Food, Drug, and Cosmetic
Act have successfully provided a framework for securing foreign
importation. Without proper federal guidance, various states,
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including Maine, have implemented legislation to facilitate the
importation of prescription drugs from other developed countries like
Canada and England.
This Article proposes two potential solutions to implement
policy on the federal level. With an eye towards Maine’s new law and
its successes, there is potential for an expanded, codified personal use
exemption. Moreover, using “qualifying” countries, or those with an
adequate level of manufacturing oversight for prescription drugs, may
provide an alternative safeguard for allowing importation.
I.

INTRODUCTION

U.S. citizens travel to other countries to obtain medical
treatment and prescription drugs because of high local prices.
Prescription drug costs in America are much higher than in other
surrounding countries. Yet, importing these medications remains
illegal. “Medical tourism” is the umbrella term used to describe going
abroad to receive medical services or treatment. Tourism can include
major surgical procedures, prescription drugs, or other medical
treatments like dentistry.1 This practice has become a lucrative trade
for the countries facilitating cheap healthcare and medications.2
The people who are harmed most by criminalizing this
conduct, however, are those who have terminal illnesses and serious
conditions but remain unable to afford costly treatments. In
desperation, some people resort to traveling across the border to
nearby countries like Canada and Mexico3 to buy prescription drugs.
1

See I. GLENN COHEN, PATIENTS WITH PASSPORTS: MEDICAL TOURISM, LAW,
AND ETHICS (2015); see also JILL R. HODGES & ANNE MARIE KIMBALL, RISKS AND
CHALLENGES IN MEDICAL TOURISM: UNDERSTANDING THE GLOBAL MARKET FOR
HEALTH SERVICes (2012) (discussing the American incentive for crossing the
border to obtain healthcare).
2
Mexico Second in Medical Tourism, Government Reports, MEX. GULF REP.
(Feb. 9, 2104),
http://www.mexicogulfreporter.com/2014/02/mexico-second-inmedical-tourism.html (noting medical tourism as a three billion dollar business for
Mexico in 2013).
3
Lorne Matalon, Desperate Patients Smuggle Prescription Drugs from Mexico,
MARKETPLACE
HEALTHCARE
(Jan
20,
2014),
http://www.marketplace.org/topics/health-care/desperate-patients-smuggleprescription-drugs-mexico; see also Michele L. Creech, Make a Run for the Border:
Why the United States Government is Looking to International Market of Affordable
Prescription Drugs, 15 EMORY INT’L L. REV. 593, 643 (2001); Helkei Tinsley,
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More recently, large numbers of people and entities locally buy bulk
foreign drugs online and have them shipped to the United States to
meet their medical needs. Needless to say, both options have received
harsh treatment by the United States government. Recognizing the
government’s policy toward importation, others have pushed for
price-caps on drugs, but to no avail.4
With the proper policy push, however, America could be on
the verge of a drug importation breakthrough. A new law on
prescription drug importation in Maine may hold at least one of the
keys to lower the high prices of prescription drugs throughout the
United States—evidence of successful implementation and safety.
The problem of high-priced prescription drugs is longstanding,5 and
remains a concern due to a number of policy barriers preventing both
efficient importation and price competition.
In response, the U.S. government has attempted to
incrementally adjust its stance to combat this increasingly difficult
area of regulation, but has yet to implement a satisfactory framework.
Such a framework, however, is possible with a close look at proposed
legislation before Congress as well as the newly passed importation
law in Maine. Moreover, Maine’s program suggests American
citizens desire better importation policy while also hinting at the
potential for success on the national level.
This Article will discuss the issues surrounding the
importation of prescription drugs into the United States and will
propose solutions that build on existing policy through economic
efficiency arguments and diverting regulatory efforts. Part I provides
the background for the problem of high-price prescription drugs and
the influence of illegality on consumer behavior. Part II will explain
the modern state of prescription importation laws, the newly passed
importation law in Maine, and the Food and Drug Administration’s
concerns with importation. Part III proposes the use of an expanded,
codified personal use exemption and an established regulation

Prescription Without Borders: America Looks to Canada for Answers to Solve the
Prescription Drug Pricing Predicament in the U.S., But is Importation Really the
Solution?, 25 HAMLINE J. PUB. L & POL’Y 437, 438 (2004).
4
See Jerry Stanton, Comment, Lesson for the United States from Foreign Price
Controls on Pharmaceutical, 16 CONN. J. INT’L L. 149 (2000).
5
See Gadler v. United States, 425 F. Supp. 244 (D. Minn. 1977).
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program for foreign manufacturers to register with the FDA along
with a permitted substance listing.
II.

THE ISSUES OF PRESCRIPTION DRUG IMPORTATION

Facilitating access to useful prescription drugs in the United
States faces two major problems. First, consumers of prescription
drugs face prohibitively high prices in the United States, which often
encourage them not to purchase necessary medications. The United
States’ free market economy, patent protection, and the lack of an
effective price board (e.g., an independent agency regulating
pharmaceutical prices) entrenches these high prices. The problem
becomes even more complicated when reviewing the heavily
entrenched pharmaceutical industry interest in legislation and attempts
to keep this industry highly profitable. Second, seeking out
prescription drugs at lower prices from countries like Canada and
Mexico is technically illegal and uncertain, and thus has a deterrent
effect for risk-averse individuals.6
A. High-Price Prescription Drugs
As mentioned in the introduction to this Article, consumers in
the United States tend to pay significantly more for prescription drugs
than people in other countries. A simple comparison to United States
price norms to Canada is illustrative of this issue—though other
countries maintain comparably better-priced pharmaceuticals as well.7
In 2004, the median prescription drug prices in Canada were as much
as 78.6% lower than those in the United States.8 In 2006, Brian Beirne
6

See Maine Enacts Law Enabling Prescription Drug Importation, CHAIN DRUG
REV. (June 28, 2013), http://www.chaindrugreview.com/newsbreaks-archives/201306-24/maine-enacts-law-enabling-prescription-drug-importation (“Americans have
accessed medication internationally for over the past decade, but federal
prohibitions on personal drug importation, while not enforced against individuals,
have deterred millions.” (internal quotation marks omitted)).
7
See Patricia M. Danzon & Michael F. Furukawa, Prices and Availability of
Pharmaceuticals: Evidence from Nine Counties, HEALTH AFFAIRS (Oct. 29, 2003),
available
at
http://content.healthaffairs.org/content/early/2003/10/29/hlthaff.w3.521.full.pdf+ht
ml.
8
Logan Beirne & Michael Tucker, Reimportation of Canadian Prescription
Drugs into the United States: Regulatory, Economic, and Policy Implications, 10
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and Michael Tucker conducted a comparative study through several
100-count medication prices and found over $1,000 in aggregate
difference between the ten selected prescriptions.9 Per the 2013
Annual Report of the Patented Medicine Prices Review Board—
Canada’s prescription drug price board—the average price ratio
shows consumers in the United States paying over double for
patented-drug products compared to Canadian consumers, a trend that
will likely increase in the coming years.10 Even generic drugs, an
oft-cited solution to high-priced prescription drugs, have shown price
hikes by as much as 17.7% in the past year.11
With such high prices, many consumers either cannot afford
their medication or make the conscious decision to “go without.” A
Consumer Reports survey returned that “28% of chronically ill adults
taking regular medications for their conditions reported skipping
doses or not filling their prescriptions because they could not afford to
pay for it,” which is a 1% increase from the year before.12 This is
particularly interesting given the inelastic demand for medical
treatment in general. That prescription drug prices are so high as to
deter filling prescriptions for chronic illnesses speaks volumes.
Why, then, does the United States struggle with prescription
drug costs? The obvious answer can be found in its economic system.

MICH. ST. U. J. MED. & L. 491, 493–94 (2006) (citing Patent Medicine Prices
Review Board Annual Report 24 (2004)).
9
Id. at 520 exh. 1.
10
See PATENT MEDICINE PRICE REVIEW BOARD ANNUAL REPORT 24 fig. 9 &
25
(2013),
http://www.pmprbcepmb.gc.ca/CMFiles/Publications/Annual%20Reports/2013/2013-AnnualReport_2013-09-15_EN.pdf (noting a 107% average price differential and that even
accounting for cost of living, the United States and Germany still have larger
consumption costs).
11
See, e.g., Ellen Jean Hirst, Generic Drug Prices Skyrocket in the Past Year
(Nov. 21, 2014), http://www.chicagotribune.com/business/ct-rising-generic-drugprices-1102-biz-201411
21-story.html; see also Susan Barry, Cost of Generic Drugs Soaring Due to
Increased Demand From Obamacare (Feb. 1, 2014), http://www.breitbart.com/BigGovernment/2014/01/31/Why-Are-Costs-For-Generic-Medications-Soaring.
12
Shari Roan, Americans Struggle to Pay for Prescription Drugs, TAKEPART
(Sept. 12, 2012), http://www.takepart.com/article/2012/09/11/americans-strugglingpay-prescription-drugs (noting survey through landline/cellphone “randomized
nationally represented sample of 4,432 adult ages 19 and older living in the
continental US”).
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Unlike the rest of the world that uses price boards to control drug
prices, the United States allows pharmaceutical companies to set the
market price.13 A few major players dominate the market through
patent control and market share, which creates a sort of oligopoly
between the pharmaceutical companies.14 This also creates a strong
incentive to price gouge consumers for high profit. To demonstrate
the incentive, the sale of prescription drugs constitutes a $300 billion
industry worldwide with profit margins as high as 30%.15 In the
United States alone, prescription drug sales yield $329.2 billion in
gross revenue.16 And due to the political clout of the pharmaceutical
lobby,17 the federal government has shown little, if any, desire to
adopt prescription price controls.18 Efforts to cap prices have been
characterized as a “slowing innovation” and “rewarding special

13

Beirne & Tucker, supra note 8, at 494 (noting “patent protection often limits
substitute products creat[ing] highly inelastic demand not seen with other
products.”).
14
Top Pharma Companies by Global Sales, PMLIVE (last visited Nov. 27,
2014), http://www.pmlive.com/top_pharma_list/global_revenues.
15
Pharmaceutical Industry, WORLD HEALTH ORG. (last visited Nov. 27, 2014),
http://www.who.int/trade/glossary/story073/en/
16
Spending
on
Medicines,
IMSHEALTH
(Apr.
15,
2014)
http://www.imshealth.com/deployedfiles/
imshealth/Global/Content/Corporate/IMS%20Health%20Institute/Reports/US_Use_
of_Meds_2013/2013_Medicine_Spending.pdf (charting medication spending,
including $329.2 billion the in US).
17
Martin L. Hirsch, Side Effects of Corporate Greed: Pharmaceutical
Companies Need a Dose of Corporate Social Responsibility, 9 MINN. J. L. SCI. &
TECH. 607, 631 (2008) (citing Julian Borger, Industry that Stalks the U.S. Corridor
of Power, GUARDIAN, Feb. 13, 2001) (noting that “[t]he pharmaceutical lobby is
recognized as the most powerful lobby in Washington); see also Beirne & Tucker,
supra note 8, at 493 (noting the pharmaceutical industry spent “$675 million on
lobbying and employ[ed] more than three thousand lobbyists between July 1998 and
July 2005”).
18
Julie Appleby, Got Insurance? You Still May Pay a Steep Price for
Prescriptions, ST. LOUIS POST-DISPATCH (Oct. 13, 2014, 10:48 AM),
http://www.stltoday.com/news/special-reports/mohealth/got-insurance-you-stillmay-pay-a-steep-price-for/article_5fd08e32-725f-535e-a7a1-5776f403f91a.html
(noting presence of state legislative response and “debate over how to slow the rapid
rise of spending on prescription drugs,” but also that “more direct government
influence on prices drug makers can charge . . . is still seen as a political
nonstarter”).
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interests.”19 As a result, consumers in the United States continue to
pay more than other countries, while nearby Mexico and Canada
enjoy attractive pricing for the same medications.20
B. Illegality
From these price concerns, some people are turning to places
like Canada and Mexico to fill their prescriptions or ordering drugs
online through Internet pharmacies. Efficient behavior dictates that
people will often seek out substitute goods in different markets if the
price is significantly lower, so long as quality remains comparable.21
However, both activities—going across the border to bring drugs back
and ordering them online from other countries—are illegal.22 Thus, as
it stands, people must choose between paying exorbitant prices,
risking prosecution from illegal importation, or going without their
medication. Wrongful importation can result in criminal charges
against the importer, depending on the amount imported, usually a
federal misdemeanor resulting in a potential year in jail and/or fine of
$1,000 per violation.23 Larger or subsequent violations are punished
with anywhere from 3–10 years in jail, or $10,000 to $250,000 in
fines, or both.24 The seizures, charges, and fines are even larger for
bulk importation from Internet pharmacies and other outlets.
Recently the FDA has even begun taking online pharmacies to
task, shutting them down and seizing their assets to make an example

19

Phil Kerpen, Price Controls for Prescription Drugs Would Reward Special
Interests and Slow Innovation, DAILY CALLER (Oct. 27, 2014, 4:30 PM),
http://dailycaller.com/2014/10/27/price-controls-for-prescription-drugs-wouldreward-special-interests-and-slow-innovation/.
20
Danzon & Furukawa, supra note 7.
21
Valentino Piana, Substitute Goods, ECON. WEB INST. (2005),
http://www.economicswebinstitute.org/glossary/substitute.htm
22
21 U.S.C. § 331(t) (prohibiting “importation of a drug in violation of section
381(d)(1), regarding importation of un-approved foreign drugs”); see also § 381
(addressing importation and reimportation of prescription drugs).
23
21 U.S.C. § 333(a)(1); see also Edward Lamb, When is it OK to Import a
Prescription Drug into the U.S. for Personal Use?, ABOUT.COM,
http://pharmacy.about.com/od/Technology/f/When-Is-It-Ok-To-Import-APrescription-Drug-Into-The-U-S-For-Personal-Use.htm (last visited Nov. 27, 2014).
24
21 U.S.C. § 333(a)–(b) (2012).
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against this type of conduct.25 The FDA has shut down several
pharmacy operations for illegal importation in violation of its
approval authority, including more well-known cases such as Rx
Depot and “Canada Care Drugs, Inc.”26 It has also made efforts to
shut down other businesses that facilitate the importation of these
prescription drugs. For example, three years ago, Google was forced
to forfeit $500 million in online advertising revenue for “assisting”
Canadian and other foreign online pharmacies to sell prescription
drugs.27 Despite attempts by the FDA to shut down these operations,
however, numerous foreign pharmacies websites exist and function
for United States citizens to buy prescription drugs online.28
The problem with the FDA’s punitive function is it deters at
least some people from seeking low-priced prescription drugs.
Though the FDA may disagree—for reasons, including safety and
innovation, discussed below—there is no real reason to continue
preventing this type of drug importation for cheaper prescription
drugs and efficient access. The basic push of this Article, then, is the
need to develop some method to allow the efficient transfer of these
foreign-manufactured drugs into the United States to allow a lowercost alternative to high-priced prescription-drug options. To explain
the necessity for this change, it is first necessary to walk through the

25

See Press Release, FDA, Permanent Court Order Halts Illegal Importation of
Prescription
Drugs
(March
31,
2006),
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm10862
7
.htm (recounting investigation and injunction of Canada Care Drugs Inc.
operations).
26
United States v. Rx Depot, Inc., 290 F. Supp. 2d 1238 (N.D. Okla. 2003)
(upholding injunction); Press Release, FDA, Permanent Court Order Halts Illegal
Importation
of
Prescription
Drugs
(Mar.
31,
2006),
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements
/2006/ucm108627.htm.
27
Press Release, Department of Justice, Google Forfeits $500 Million
Generated By Online Ads & Prescription Drug Sales by Canadian Online
Pharmacies
(Aug.
24,
2011),
http://www.justice.gov/
opa/pr/google-forfeits-500-million-generated-online-ads-prescription-drug-salescanadian-online (explaining that it is illegal to aid or facilitate importation and
marketing of illegal prescription drugs to U.S. citizens).
28
See, e.g., Canadian Generic Pharmaceutical Association, CGPA,
http://www.canadiangenerics.ca/
en/index.asp (last visited Nov. 2, 2104).
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current state of prescription drug law and its inadequacies at
addressing these issues of access, price, and importation.
III.

CURRENT IMPORTATION LAW

This Part will address the current state of the law surrounding
prescription drug importation in two major parts. First, it will discuss
issues under the Federal Food, Drug, and Cosmetic Act (FFDCA),
including major amendments and importation exceptions. Second, it
will evaluate the concerns—safety and innovation—raised by the
FDA in maintaining the prohibition on prescription drug importation.
Third, it will discuss the various attempts at state regulation of
prescription drug importation. Fourth, this Part will address Maine’s
new prescription drug importation legislation as a laboratory for
federal policy. These issues will be discussed in turn.
A. Federal Food, Drug, and Cosmetic Act
The FDA regulates all aspects of prescription drugs in the
United States, including manufacturing, production, and transport. Its
original authority comes from the Federal Food, Drug, and Cosmetic
Act of 1938, which also allows it to regulate the import and export of
prescription drugs.29 Under the Act, the FDA has the authority to
establish procedures for the monitoring and approval of new drugs.30
Its power extends to enforcement against violations of these regulated
areas under the FFDCA as well.31 As discussed above, the FDA also
leads investigations to seize wrongfully imported and counterfeit
drugs.32 The United States Customs and Border Protection (CBP),
with FDA guidance, helps to enforce prescription drug mandates

29

21 U.S.C. § 381(d) (2012).
21 C.F.R. pt. 314 (2014).
31
See 21 C.F.R. § 1.4 (2001).
32
Imported Drugs Raise Safety Concerns, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/
Drugs/ResourcesForYou/Consumers/ucm143561.htm (referencing a 2002 FDA
investigation where agents uncovered “more than 25,000 counterfeit Viagra
pills . . . [supplied] from China and India”) (last updated Aug. 24, 2011).
30
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against importation.33 This includes a ban on “the importation of
prescription drugs that were purchased outside the United States.”34
All drugs imported into the United States require FDA
approval.35 The FDA has this authority through the power to regulate
drugs issued into “interstate commerce,” which also includes foreign
importation.36 Additionally, drugs imported into the United States
must conform to labeling and manufacturing requirements set by the
FDA, which also happens to be among the strictest standards set by a
regulating agency worldwide.37 Once inside the United States,
approved prescription drugs are processed through a “closed”
distribution system.38 As such, the only people able to receive the
imports are U.S.-licensed pharmacists and wholesalers.
1. Personal Use Exemption
Due to difficulties regulating individual importation, in 1954
the FDA issued a personal use exemption for individual people to
import up to a ninety-day supply under certain conditions.39 The
statute provides the FDA power to “exercise discretion to permit
individuals to make such importations in circumstances in which the
importation is clearly for personal use . . . [and] the prescription drug
or device imported does not appear to present an unreasonable risk to
the individual.”40 The personal use exemption, however, is a
discretionary guidance on the FDA’s choice to allow importation
rather than a legally binding exception that importers may rely upon.41
33

Prohibited and Restricted Items, U.S. CUSTOMS & BORDER PROT.,
http://www.cbp.gov/travel/
international-visitors/kbyg/prohibited-and-restricted-items (last visited Nov. 2,
2014).
34
Id.
35
Imported Drugs Raise Safety Concerns, supra note 32.
36
Id.
37
Id. (explaining FDA requirements and foreign-registered manufacturer
inspections).
38
Id.
39
Id.; see also Prohibited and Restricted Items, supra note 33.
40
21 U.S.C. § 384(j)(1)(B) (2003).
41
See Imported Drugs Raise Safety Concerns, supra note 32; Peter S. Reichertz
& Melinda S. Friend, Hiding Behind Agency Discretion: The Food and Drug
Administration’s Personal Use Drug Importation Policy, 9 CORNELL J. L. & PUB.
POL’Y 493 (2000).
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There is no right to import prescription drugs for personal use. Thus,
people looking to import prescription drugs for personal use lack
certainty and guidance.
In 1988, the FDA used the personal use exemption to save
regulatory resources and allow importation of new AIDS drugs
against an epidemic. It modified the personal use exemption for the
benefit of drugs where no equivalent was available, or approved for
use, in the United States.42 The personal use exemption currently
includes the following factors for use in the FDA’s discretionary
ruling whether to enforce:
Ø if the intended use is for a serious condition without
effective domestic treatment available;
Ø if the product is considered to represent an unreasonable
risk;
Ø if the individual seeking to import affirms in writing that it
is for personal or patient use and provides the name and
address of the U.S.-licensed doctor responsible for the
treatment;
Ø if there is evidence that the drug is for continuation of a
treatment begun in a foreign country;
Ø if the product is for personal use and is a three-month
supply or less and not for resale, since larger amounts
suggest commercial use; and
Ø if there is a known commercialization or promotion to U.S.
residents by those involved in distribution of the product.43
While this exemption would seem to provide a reasonable allowance
for personal importation of necessary treatment, in reality it is a
narrow application with difficult-to-satisfy criteria. Specifically, it is
difficult to imagine a serious condition in modern times where the

42

See Benten v. Kessler, 799 F. Supp. 281, 282 (E.D.N.Y. 1992) (criticizing the
personal use exemption as an “ill-considered promulgation” in a case involving an
FDA import alert banning importation of RU486, an experimental abortion drug);
see also Imported Drugs Raise Safety Concerns, supra note 32.
43
Marvin A. Blumberg, Information on Importation of Drugs, U.S. FOOD &
DRUG ADMIN, http://www.fda.gov/ForIndustry/ImportProgram/ucm173751.htm
(last updated June 30, 2010); See also Imported Drugs Raise Safety Concerns, supra
note 32.
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United States has no comparable “effective domestic treatment.”44
Moreover, drugs purchased in a foreign country, even by the same
name as a United States counterpart, are likely not FDA-approved and
would not meet the importation standards under its regulation.45
The personal use exemption has largely been ineffective at
either providing relief for importation or helping to regulate the flow
of unapproved, and thus illegal, prescription drugs. Not only has the
personal use exemption failed to provide a safe haven in legitimate
cases, it has not discouraged attempts at technically illegal
importation by people willing to risk violation and has not helped to
decrease prices, nor increase access.46 On the other hand, it has
discouraged many people who need medication from seeking it out at
the risk of committing a crime.47
2. Reimportation
Another commonly posited solution to high-price prescription
drugs in the United States is the practice of so-called drug
“reimportation.” Drug reimportation is when American drug
manufacturers export their products to foreign countries, adjust them
to price norms in those countries, and designate them for sale there.48
Once the product is abroad, price boards of nearly all other developed
countries49 dictate a lower price for the exported drug. At this point,
44

As a matter of history, the personal use exemption was most widely used to
justify importation of early experimental Cancer medication and some abortion
drugs. See, e.g., Benten, 799 F. Supp. at 281; see also Gadler, 425 F. Supp. at 244.
45
See 21 U.S.C. § 331 (2013) (prohibiting interstate shipment of unapproved
new drugs).
46
Importation of Drugs into the United States: Hearing Before the Subcomm.
on Oversight and Investigations of the H. Comm. on Energy and Commerce, 107th
Cong. (2001) (statement of William K. Hubbard, Senior Associate Commissioner
for Policy, Planning, and Legislation, Food and Drug Administration), available at
http://www.fda.gov/NewsEvents/Testimony/ucm115214.htm (discussing personal
importation and oversight issues in mail and over the border).
47
See Maine Enacts Law Enabling Prescription Drug Importation, supra note
6.
48
See Imported Drugs Raise Safety Concerns, supra note 32; see also Monali J.
Bhosle & Rajesh Balkrishnan, Drug Reimportation Practices in the United States,
3(1) THERAPEUTICS & CLINICAL RISK MGMT. 41, 41–42 (2007).
49
Paula Tironi, Pharmaceutical Pricing: A Review of Proposals to Improve
Access and Affordability of Prescription Drugs, 19 ANNALS HEALTH L. 311, 352
(2010).
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individual consumers may solicit particular prescriptions from foreign
pharmacies at a lower price and have them shipped back into the
United States at a minimal cost that generates a net savings.50 This
idea also presents a price discrimination issue, whereby some
consumers willing to pay for higher-price drugs will buy them
domestically, while others less willing will choose to go abroad for
their medications.51 Further, perhaps the idea of needing to export
products to a foreign market where the price is regulated and then
shipping it back domestically to gain savings demonstrates the
absurdity of the current price system as it exists.
On the flip side, the manufacturer, in theory, could reimport
them into the United States and pass along the savings to consumers
locally with reduced prices.52 Such is the theory of the FDA to the
extent that it accepts the idea of reimportation, but this has yet to
become an accepted practice.53 There is also very little incentive for
manufacturers to engage in reimportation themselves, as imports back
into the country must still abide by the FDA’s costly regulations.54 On
the other hand, pharmaceutical companies still benefit from having
this extended market to tap into these consumers who are less willing
to pay high prices domestically.
Further complicating this problem, it is difficult to track the
origin of these “reimported” drugs,55 which has resulted in the FDA
not implementing any reimportation policy to date.56 Given regulatory
resource concerns, the FDA has trouble ensuring that the prescriptions
coming back through the mail were, in fact, manufactured in the
United States. If not manufactured domestically, it is unlikely that the
drugs will meet the FDA’s requirements, and are thus unacceptable

50

Bhosle & Balkrishnan, supra note 48, at 41–42.
See Beirne & Tucker, supra note 8, at 501 (discussing European prescription
drug model and prohibited price discrimination between countries).
52
Bhosle & Balkrishnan, supra note 48.
53
See Imported Drugs Raise Safety Concerns, supra note 32; see also Beirne &
Tucker, supra note 8, at 493 (noting that PMAA “does not explicitly prohibit
importation from other countries that adhere to safety requirements”). The issue
becomes that meeting such requirements is extremely complicated, and thus
prohibitive. Without making it officially illegal, it makes the reimportation de facto
illegal.
54
See Imported Drugs Raise Safety Concerns, supra note 32.
55
Bhosle & Balkrishnan, supra note 48, at 41–42.
56
See Carmona, infra note 65 and accompanying text.
51
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for importation or sale in the United States. Even where the
manufacturing regulation appears to be on par with the United States’,
the FDA denies access.57 Furthermore, the burden of meeting
importation standards rests with the importer and is often impossible
to meet, even for the original manufacturers.58
Nonetheless, it would seem that such an option, helping to cut
cost, would still be sufficient. Per FDA policy, however, prescription
drug reimportation is still viewed with suspicion.59 The FFDCA also
includes several labeling and approval provisions that make it
extremely difficult to reimport.60 Some scholars, on the contrary, have
argued that reimportation is a valid option to encourage cost
competition and eventually encourage government-mandated price
caps on prescription drugs.61 To date, however, the FDA has yet to
implement a reimportation policy, despite several FFDCA
amendments aimed at integrating access and subsidizing prescription
drug prices, which will be discussed in the following section.
3. Recent Amendments
There have been a number of FFDCA amendments in response
to this issue of high prices and prescription drug access, but none have
been sufficient at addressing the problem as it stands today, either
through inadequate alternative solutions or failed implementation.
This subsection will discuss the three most pertinent amendments in
turn: (1) the Medicine Equity and Drug Safety Act of 2000; (2) the
Medicare Prescription Drug, Improvement and Modernization Act of
2003; and (3) the Food and Drug Administration Safety and
Innovation Act of 2012.

57

See Imported Drugs Raise Safety Concerns, supra note 32.
Id. Additionally, the FDA has recently proposed counterfeit-resistant
technology and other special requirements to make it more difficult to import
prescription drugs. Beirne & Tucker, supra note 8, at 505.
59
See Imported Drugs Raise Safety Concerns, supra note 32; Beirne & Tucker,
supra note 8, at 505 (explaining safety risks of reimportation).
60
Beirne & Tucker, supra note 8, at 500.
61
Id. at 519. But see Devin Taylor, Importing a Headache for Which There’s
No Medicine: Why Drug Reimportation Should and Will Fail, 15 J.L. & POL’Y
1421, 1468 (2007) (advocating that drug reimportation is too dangerous).
58
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In 2000, Senator Jim Jeffords proposed the Medicine Equity
and Drug Safety Act (MEDS) in Congress.62 The Act had the
objective of achieving reimportation success but was never passed in
Congress due to alleged safety concerns by the Secretary of Health.63
The bill recognized that “the cost of prescription drugs for Americans
continue to rise at an alarming rate” and that “many life-saving drugs
are available in countries other than the United States at substantially
lower prices.”64 As such, it provided authority for the Secretary of
Health to create and implement regulatory frameworks regarding both
importation and reimportation of prescription drugs from foreign
countries, including Canada.65
As a renewed effort to address the issues of importation and
popular pressure against high prescription prices, in 2003, Congress
passed the Medicare Prescription Drug, Improvement and
Modernization Act (MMA).66 This amendment implemented Part D
Medicare benefits and also permitted the limited importation of
certain drugs from Canada, closely mirroring the factors of the
personal use exemption.67 While this amendment provided authority
to allow importation, once again the Secretary of Health and Human
Services never used the discretion to initiate this program.68 Thus, it
subsidized some useful prescriptions through its Part D benefit, but
the MMA amendment was largely ineffective in addressing
importation concerns and never really provided legal support for
62

Medicine Equity and Drug Safety Act of 2000, S. 2520, 106th Cong. (2000),
available at https://www.govtrack.us/congress/bills/106/s2520#overview.
63
Id.; see also Prescription Drug Re-Importation Question and Answer Sheet,
AARP,
http://assets.aarp.org/www.aarp.org_/articles/international/ReimportationQA.pdf.
64
S. 2520 § 2 (referred to the Committee on Health, Education, Labor, and
Pensions).
65
Id. § 3.
66
Report of the HHS Task Force on Drug Importation: Hearing Before the
Committee on Health, Education, Labor, and Pensions, U.S. Senate (2005)
[hereinafter
Report
HHS
Task
Force],
available
at
http://www.hhs.gov/asl/testify/t050216b.html (statement of Richard H. Carmona,
Surgeon General of the U.S. Public Health Service).
67
Daniel L. Pollock, Blame Canada (And the Rest of the World): The TwentyYear War on Imported Prescription Drugs, 30 SETON HALL LEGIS. J. 331, 349–51
(2006); see Beirne & Tucker, supra note 8, at 500 (explaining MMA inclusion of
Canadian imports and similarities to the personal use exemption).
68
Report HHS Task Force, supra note 66.
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importation. Rather, the FDA continued to take a “strong stance”
against importation of prescription drugs for safety reasons, which
later led to other creative state alternatives to federal law.69
The most recent amendment to the FFDCA, passed on July 9,
2012, as the Food and Drug Administration Safety and Innovation Act
(FDASIA), was likewise inadequate at addressing the issue of drug
importation,70 although the amendment acknowledges that a
significant portion of finished drugs and active ingredients come from
overseas sources.71 As a part of its content, the amendment expands
the FDA’s authority to protect and monitor the drug supply chain of
approved prescription drug materials and manufacturer
reimportations.72 While providing for safer supply chains for
U.S.-produced pharmaceuticals, the amendment does little, if
anything, to address importation or price controls.73
B. FDA’s Concerns
The Agency puts forward two major concerns when discussing
its decision to continue prohibiting importation: (1) the inability to
ensure the safety of imported substances, and (2) that cheaper
imported drugs would undercut the incentive for pharmaceutical
companies to invest in research and development. The following
subsections will discuss these issues in turn.
1. Safety
FDA importation policy mentions safety as a major concern
for prescription drug importation. The safety concern is that the FDA
69

Jennifer Micheletto, The Illinois Prescription Drug Plan: Will it Last? An
Analysis of the Current State of Health Care, Congressional Efforts to Lower
Prescription Drug Costs, and Illinois’ Response to High Prices, 9 DEPAUL J.
HEALTH CARE L. 1261, 1261 (2006).
70
Food and Drug Administration Safety and Innovation Act (FDASIA), FOOD &
DRUG
ADMIN.,
http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosme
ticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/
(last
updated
October 28, 2014).
71
Id. (noting 40% of all finished drugs and 80% of the raw ingredients come
from abroad).
72
Id.
73
Id.
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cannot know where certain drugs originate and is unable, given its
resources, to verify the content of all imports.74 While this problem
certainly exists, especially for developing countries and indeterminate
sources, it is significantly overstated as a barrier for effective
importation. For unapproved as well as approved drugs, the FDA
typically cites safety standards and dangerous counterfeiting as the
reasons for denying access to importation.75 Safety concerns receive
disproportionate media coverage, but are not as significant as the FDA
suggests, especially for countries with comparable manufacturing and
transport regulatory schemes.
The FDA’s concern for drug safety consists of at least six
factors listed on its website and in importation literature: (a) Quality
Assurance Concerns, (b) Counterfeit Potential, (c) Presence of
Untested Substances, (d) Risks of Unsupervised Use, (e) Labeling and
Language Issues, and (f) Lack of Information.76 Interestingly enough,
all of these standards basically say the same thing, namely that drugs
are not “safe.”
In determining how to best handle this issue of safety, the
FDA has implemented a “risk-based” approach to importation.77
Under this approach, the FDA chooses when to exercise its
prosecutorial discretion depending on how much of a risk is posed by
a given importation, which is often denoted by “import alerts” for

74

FDA Operation Reveals Many Drugs Promoted as “Canadian” Products
Really Originate From Other Countries, FOOD & DRUG ADMIN. (Dec. 16, 2005),
available
at
http://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/2005/ucm108534.htm (alleging “Canadian” drugs
typically originate in other countries).
75
See Imported Drugs Raise Safety Concerns, supra note 32 (citing retired
Regulatory Affairs officer, Joseph McCallion, stating, “If you buy drugs that come
from outside the U.S., the FDA doesn't know what you're getting, which means
safety can't be assured” (internal quotation marks omitted)).
76
Looks Can Be Deceiving, FOOD & DRUG ADMIN. (Apr. 3, 2012), available at
http://www.fda.gov/Drugs/ResourcesForYou/ucm078900.htm.
77
Import, Counterfeit, and Unapproved Drugs: Hearing before the Subcomm.
on Oversight and Investigations H. Comm. on Energy and Commerce (2003)
(statement of William K. Hubbard, Associate Commissioner for Policy and
Planning), available at http://www.fda.gov/NewsEvents
/Testimony/ucm161030.htm (noting the FDA has responded to the influx of
importations by “employing a risk-based enforcement strategy to deploy our
existing enforcement resources in the face of multiple priorities”).
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particularly dangerous shipments.78 It is for this reason that the FDA’s
enforcement objectives have largely targeted the businesses that
facilitate the importation rather than the individuals seeking the
medication.79 Thus, for practical purposes, importation only becomes
subject to an enforcement action once it becomes “commercial” in
nature, or large enough to register profit as a business.80 To reflect this
reality, recently the FDA proposed regulation allowing authority to
seize and destroy improperly imported prescription drugs valued at
less than $2,500, with the purpose of “increasing the integrity of the
drug supply chain.”81
This approach has received heavy criticism because of its
apparent support for industry profit margins rather than securing
safety for consumers, or effective deterrence.82 The same critics have
also noted that the FDA often fails to test the drugs it seizes in busting
up these operations—suggesting less than a true concern for safety by
the FDA.83 It is also worth noting that enforcement that takes this
approach removes one of the best consumer safeguards to consumer
purchasing—the vendor. Entities, like online pharmacies and
wholesalers, are often in a better position to negotiate precautions and
safeguards for consumers.84
Instead, the enforcement policy encourages behavior such that
individuals, navigating the vast sea of prescription drugs online, are
the ones bearing the safety risk, although perhaps not the legal one, of
the imported drug because the FDA refuses to recognize legitimate
sellers in this arena.85 Prosecuting vendors functions to discourage
legitimate companies from selling to U.S. consumers, while leaving
78

Id.
JODY FEDER, CONG. RESEARCH SERV., RL 32191, PRESCRIPTION DRUG
IMPORTATION AND INTERNET SALES: A LEGAL OVERVIEW, CRS 12-13 (2004).
80
See id.
81
See Administrative Destruction of Certain Drugs Refused Admission to the
United States, 79 Fed. Reg. 25758 (Proposed May 6, 2014) (to be codified at 21
C.F.R. pt. 1), available at https://www.federalregister.gov/articles/2014/05/06/201410304/administrative-destruction-of-certain-drugs-refused-admission-to-the-unitedstates; see also 21 U.S.C. § 381(b) (explaining disposition of refused articles).
82
See id.
83
FEDER, supra note 79.
84
Bruce Watson, Need Cheap Medication? Move to Maine, DAILYFINANCE
(Oct.
13,
2013),
http://www.dailyfinance.com/on/cheap-medication-mainecanadian-prescription-drugs/.
85
See id.
79
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the illegitimate vendors who will risk the sale regardless. Yet, despite
FDA warnings about safety and uncertainty for imported drugs, some
consumers are still purchasing these products from abroad.86 Even
still, as a practical matter, the FDA policy turns a blind eye to the
reality of most personal use importations,87 which begs the question:
if knowing prohibition does not work and the FDA is concerned about
safety, then why not regulate actively, instead of maintaining this
umbrella prohibition?
To continue discouraging the leap to a more liberal
importation standard, the FDA periodically releases a story about the
safety concerns and unpredictability of imported drugs.88 Likewise, it
also attempts to debunk the “myth” that Canadian prescription drugs
are somehow cheaper.89 While, at the same time, pharmaceutical
companies continue to import their raw materials from foreign
countries and even manufacture abroad.90 In one instance, the FDA
86

FDA Finds Consumers Continue to Buy Potentially Risky Drugs Over the
Internet: Practice Puts Consumer at Risk and May be More Expensive than
Domestic Purchasing, FOOD & DRUG ADMIN. (July 2, 2007),
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm10894
6.htm; see also FDA Test of Prescription Drugs from Bogus Canadian Website
Show All Products are Fake and Substandard, FOOD & DRUG ADMIN. (July 13,
2004),
http://www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/2004/ucm108320.htm (explaining continued importation by
United States citizens despite FDA warnings about safety).
87
Neil Osterweil, The Letter (and Spirit) of Drug Import Law, WEBMD,
http://www.webmd.com/
healthy-aging/features/letter-and-spirit-of-drug-import-laws (last visited Nov. 2,
2014).
88
Aaron Carroll, How Safe are your prescription drugs, CNN OPINION (Feb.
24, 2014), http://www.cnn.com/2014/02/25/opinion/carroll-drugs-imported-safety/;
see also FDA Test Results of Prescription Drugs from Bogus Canadian Website
Show All Products Are Fake and Substandard, FOOD & DRUG ADMIN. (July 13,
2004),
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/
2004/ucm108320.htm (identifying Canadian drugs as fakes).
89
See Linda Bren, Study: U.S. Generics Cost Less than Canadian Drugs, FOOD
&
DRUG
ADMIN.
(July,
2004),
http://www.fda.gov/Drugs/ResourcesForYou/ucm134441.htm.
90
See e.g., Jennifer L. Halser, Canadian Pharmacies: A Prescription for a
Public Health Disaster, 54 DEPAUL L. REV. 543 (2005); Regulatory Information,
Food and Drug Administration Safety and Innovation Act, FOOD & DRUG ADMIN.,
http://www.fda.gov/RegulatoryInformation/Legislation/
FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/F
DASIA/ (last updated Aug. 28, 2014) (noting “40 percent of finished drugs being
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issued a press release detailing a 2003 drug seizure. It found that 88%
of packaged drugs in the inspected shipment did not meet FDA
standards.91 In another instance, the FDA seized packets in 2005 and
found that 88% of the drugs, alleged from Canada, were produced in
27 other countries.92 The National Association of Boards of Pharmacy
(NABP), a professional association of pharmacists, has also been
implicated in these attacks through sponsoring studies about the safety
of Canadian online pharmacies.93
Studies show, however, that the risks of counterfeiting and
safety are probably much higher in developing countries than others
with regulation similar to the United States. It is estimated that about
30% of all drugs in developing countries are counterfeit,94 while only
an estimated 1% of all drugs face this problem when exported from a
developed country.95 Thus, importing from a developing, rather than
developed, country has a significantly higher risk of being counterfeit.
imported, and nearly 80 percent of active ingredients coming from overseas
sources.”).
91
Gilbert Ross, Why Drug ‘Reimportation’ Won’t Die, WALL ST. J. (Jan. 7,
2010),
http://online.wsj.com/articles/SB10001424052748704842604574642184130409874
.
92
See FDA Operation Reveals Many Drugs Promoted as “Canadian” Products
Really Originate From Other Countries, supra note 74.
93
Save Money by Ordering Drugs from Canada? Not so Fast, CONSUMER REP.
NEWS
(Oct.
27,
2011
06:08
AM),
http://www.consumerreports.org/cro/news/2011/10/save-money-by-ordering-drugsfrom-canada-not-so-fast/index.htm (attacking Canadian prescription drugs). The
study reviewed 8,300 online pharmacies and found that around 3 % were actually
“legitimate” operations. Id. Furthermore, 85% did not require a valid prescription
from the customers, 44% offered foreign drugs or FDA-unapproved drugs, and 25%
had physical addresses outside of the United States. Id.
94
Judy Stone, Counterfeit Drugs: A Deadly Problem, SCI. AM. BLOG (Aug. 20,
2012),
http://blogs.scientificamerican.com/molecules-tomedicine/2012/08/20/counterfeit-drugs-a-deadly-problem/; see also Priya Shetty,
Counterfeit Drugs: Facts & Figures, SCIDEV.NET (Mar. 30, 2011),
http://www.scidev.net/global/health/feature/counterfeit-drugs-facts-figures-1.html.
95
Medicines:
Spurious/Falsely-Labelled/Falsified/Counterfeit
(SFFC)
Medicines,
WORLD
HEALTH
ORG.
(May
2012),
http://www.who.int/mediacentre/factsheets/fs275/en/ (noting that “incidences of
SFFC medicines is extremely low” in Australia, Canada, Japan, New Zealand, the
United States, and the European Union); see also Counterfeit Medicines, WORLD
HEALTH
ORG.
(Nov.
14,
2006),
http://www.who.int/medicines/services/counterfeit/impact/ImpactF_S/en/.
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At 1% counterfeiting for developed countries, however, the risk seems
fairly minimal in reality.
The FDA argues that these safety concerns expand to all
foreign countries, but evidence suggests that there is no such concern.
In fact, some argue that safety concerns regarding countries like
Canada are “unwarranted” and that safety standards in these countries
are “very similar” to those required in the United States.96 For
example, manufacturers in Canada must also comply with the “Good
Manufacturing Practices” promulgated by the FDA,97 the
quintessential quality standard requirement imposed on drug
manufacturers.98 Several agencies, including the North American
Pharmacy Accreditation Commission and Health Canada’s
Therapeutic Product Directorate, regulate compliance and quality
assurance.99 The process for approval also includes licensing of
individuals engaged in the production and oversight of prescription
drug manufacturing.100 Research also suggests that in Canada the
“incident reporting of internal process errors [is] more rigorous […]
than in the US,” which suggests a stronger feedback loop to minimize
faulty drugs making it to the consuming public.101
Similar to Canada, many European countries, among others,
also utilize similar approval and quality assurance processes for
prescription drugs.102 While some aspects of the process might differ,

96

Beirne & Tucker, supra note 8, at 503–04 (“United States and Canada have
comparable requirements at virtually every step in the process. Both nations require
that quality control units test both the raw materials prior to production and the
finished product.”); see also Petra Brhlikova, Ian Harper & Allyson Pollock, Good
Manufacturing Practice in the Pharmaceutical Industry, CTR. FOR INT’L PUB.
HEALTH
POLICY
(July
2–3,
2007),
http://www.csas.ed.ac.uk/__data/assets/pdf_file/0011/38828/
GMPinPharmaIndustry.pdf.
97
Id. at 504.
98
Facts About Current Good Manufacturing Practices (cGMPs), FOOD &
DRUG
ADMIN.,
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/ucm16910
5.htm (last updated Oct. 23, 2014).
99
Beirne & Tucker, supra note 8, at 504.
100
Id.
101
Id.
102
See Medicines, MED. PRODUCTS AGENCY (Feb. 5, 2006),
http://www.lakemedelsverket.se/
english/overview/About-MPA/Activities/Medicines/ (outlining Sweden’s regulatory
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studies suggest that the European Union still achieves comparable
safety levels while avoiding the delays of the FDA’s process.103 The
FDA has even recognized the utility of sharing approval methods and
process discussions with European and Scandinavian countries like
Sweden.104
2. Innovation
The other argument that the FDA uses to justify prohibiting
importation is a concern for stifled innovation. Some scholars argue
that importation would be the first step in effective price controls for
pharmaceuticals,105 while others feel that it would kill the incentive
for investments in developing new, cutting-edge prescription drugs.106
The basic argument is that allowing “backdoor price controls”—
through cheap imported drugs—will have this same effect.107
Allowing importation will kill demand in the high-price market for
pharmaceuticals, drastically cutting profits, which in turn will be
siphoned from R&D operations.
Despite this concern, it seems that there will always be
consumers willing to pay high prices for brand-name goods.108
Moreover, the federal government is often responsible for funding the
majority of the most important pharmaceutical research for public

agency process for approving new medicines and quality control measures used to
maintain safety); see also Pharmaceutical Administration and Regulations in Japan,
JAPAN
PHARM.
MFG.
ASS’N
24
(2010),
http://apps.who.int/
medicinedocs/documents/s18577en/s18577en.pdf (requiring adherence to the Good
Manufacturing Practice for quality control of Japanese manufactured prescription
drugs).
103
See Ines M. Vilas-Boas & C. Patrick Tharp, The Drug Approval Process in
the U.S., Europe, and Japan, 3 J. MANAGED CARE PHARMACY 459 (1997),
http://amcp.org/WorkArea/Download
Asset.aspx?id=5884.
104
FDA – Swedish National Board of Health, FOOD & DRUG ADMIN. (Mar. 5,
2009),
http://www.fda.gov/InternationalPrograms/Agreements/MemorandaofUnderstandin
g/ucm107628.htm.
105
See Beirne & Tucker, supra note 8, at 493.
106
Ross, supra note 91.
107
Id.; see also Kerpen, supra note 19.
108
This issue links into the inelastic demand for prescription drugs and the
demand for luxury goods in the United States in times of higher income.
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health.109 Studies have found that between 1965 and 1992, as much as
66% of the funding for important drugs was publicly-provided.110
Thus private R&D is not the only, and certainly not the most
significant, source of funding to develop important pharmaceuticals.
All things being equal, maintaining public funding is perhaps more
important than concerns about private incentives to develop.
Moreover, pharmaceutical companies also receive such high profits—
at around 30%111—that cutting some profits will likely not
significantly affect R&D.112
C. State Importation Legislation
In the early 2000s, given the lack of viable alternatives for
cheap medicine, states began to implement their own laws to allow for
the importation of prescription drug from certain countries including
Canada.113 State intervention programs existed on a spectrum: some
involved as little as informing consumers about the option for
Canadian or foreign prescription drugs,114 while others implemented
contractual plans with foreign pharmacies and wholesalers to facilitate
the purchase of prescription drugs.115 In particular, the Illinois “ISaveRx” plan established “benefit-manager” relationships to purchase
pharmaceuticals through countries like Canada, Ireland, and the
United Kingdom.116 This more involved type of state intervention still
only utilized personal use importation rather than facilitating state
importation of FDA-restricted prescription drugs.117
Not surprisingly, the FDA and pharmaceutical syndicates
responded negatively to both types of programs regardless of the

109

Beirne & Tucker, supra note 8, at 514.
Id. at 514.
111
Pharmaceutical Industry, supra note 15.
112
See Beirne & Tucker, supra note 8, at 515.
113
Micheletto, supra note 69, at 1261; Lynn Sweet, Illinois Defying Feds,
Importing Rx Drugs; But FDA is Threatening to Take State To Court, CHI. SUNTIMES, Aug. 17, 2004, at 8.
114
Micheletto, supra note 69, at 1277–78 (discussing Minnesota plan to inform
consumers about “state-approved Canadian pharmacies” but not being “directly
involved in importing prescription drugs” (internal quotation marks omitted)).
115
Id. at 1279.
116
Id. (citing Anna Wilde Mathews, Illinois to Set Up a Program to Promote
Drug Importation, WALL ST. J., Aug. 17, 2004, at D4).
117
Id. at 1279–80.
110
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degree of state involvement.118 It is difficult to ignore the benefit
derived by these state programs in passing on savings to its citizens.119
Despite the relative savings provided by these programs, the states
that explored this type of legislation largely abandoned them in 2006
when the prescription-drug benefit was added to Medicare via the
MMA amendment implementation,120 as well as other programs
expressly denied by the FDA.121 Others states, deterred by fears of
violating federal law and risking infringement on FDA jurisdiction,122
never implemented their own program, but nonetheless recognized the
problem of high-price prescription drugs. Yet, even today, states
continue attempting to contravene FDA policy and formulate
importation programs,123 which shows the continued interest for
import policy reform.
D. Maine’s New Legislation
The most recent state program to emerge is Maine’s “Act to
Facilitate the Personal Importation of Prescription Drugs from

118

Id. at 1278–80.
See, e.g., Serena Lipski, Excessive Pricing and Pharmaceuticals: Why the
Federal Patent Act Does Not Preempt State Regulation of Pharmaceutical Prices,
39 U. TOL. L. REV. 913, 916–17 (2008); Micheletto, supra note 69, at 1261 (noting
that Illinois state important law had “hopes of saving its citizens a significant sum of
money”).
120
See Kristin E. Schleiter, Court Support for FDA Regulation of Drug
Importation, 11 AMER. MED. ASSOC. J. OF ETHICS 521 (2009); see also Jennifer
Levitz & Timothy W. Martin, Maine to Allow Prescription-Drug Imports, WALL
ST. J. (last updated Oct. 11, 2013), http://online.wsj.com/articles/
SB10001424052702303442004579123613325473946; Medicine Equity and Drug
Safety Act of 2000, supra note 66.
121
Vermont v. Leavitt, 405 F. Supp. 2d 466 (D. Vt. 2005); see also Schleiter,
supra note 120.
122
Ark. Att’y Gen. Op. No. 2001-035 (Mar. 15, 2001); Tenn. Att’y Gen. Op.
No. 06-019 (Jan. 27, 2006); Tenn. Att’y Gen. Op. No. 05-083 (May 16, 2005)
(deferring to FDA regulation and federal preemption); Tex. Att’y Gen. Op. No. GA0384 (Dec. 21, 2005).
123
Jackie Farwell, British Pharmacy Chain Launches Online Drugstore for
Maine
Consumers,
BANGOR
DAILY
NEWS
(Nov.
27,
2014),
http://bangordailynews.com/2014/10/07/health/british-pharmacy-chain-launchesonline-drugstore-for-maine-consumers/.
119
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International Mail Order Prescription Pharmacies.”124 Under the law,
Maine residents may import prescription drugs from licensed
pharmacies in Australia, Canada, New Zealand, and the United
Kingdom.125 The Maine Pharmacy Association, along with
representatives of the pharmaceutical industry, recently filed suit
challenging the law on various grounds.126 While the claims by
pharmaceutical interests were dropped for lack of standing, the suit
remains ongoing.127
In discussing the Maine law, those in opposition use the same
safety rhetoric used against the federal level policy.128 And as some
suggest, perhaps it is more of a “turf” issue surrounding
pharmaceutical profits rather than safety.129 Moreover, the benefits
recognized by the program are quantifiable. Maine has consistently
pushed the envelope in this arena since the first state programs back in
the early 2000s.130 Between the years of 2004–2012, Maine residents
experienced $3.2 million aggregate savings on prescription drugs.131
Given that states have historically acted as the laboratories for federal
policy,132 Maine’s success is a useful indicator for further individual
124

S.P. 60, L.D. 171 126th Leg., 1st Reg. Sess. (Me. 2013),
http://www.mainelegislature.org/
legis/bills/getPDF.asp?paper=SP0060&item=2&snum=126.
125
See Maine Enacts Law Enabling Prescription Drug Importation, supra note
6.
126
Complaint, Maine Pharmacy Ass’n v. Mills, No. 1:13-cv-00347-NT (D. Me.
2013), http://freepdfhosting.com/7c2bcf9ba9.pdf; Kurt R. Karst, Mainers and FDC
Act Preemption “In,” and PhRMA and Foreign Commerce Clause “Out” in
Dispute Over Drug Importation Law, FDA L. BLOG (May 20, 2014),
http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2014/05/page/2/.
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http://blogs.wsj.com/pharmalot/2014/10/08/in-maine-the-british-are-coming-to-sellprescription-medicines-online/.
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2014),
http://www.citizenvox.org/2013/10/24/maine-drug-reimportation-law-may-benefitconsumers/.
129
Id.
130
Id.
131
Id.
132
New State Ice Co. v. Liebmann, 285 U.S. 262, 386–87 (1932) (“To stay
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state policy reform. Not to mention, a fifty-state system of
prescription drug import regulation would prove an administrative
nightmare. A single regulator concerned with safety is important, but
the FDA needs to relax its limits.
IV.

NORMATIVE SOLUTION

A solution to the limited access and high price of prescription
drugs is complicated, but attainable. Potential solutions to this issue
could include everything from skipping FDA-approval rounds for
desired importations, implementing price control boards, or closing
patent loopholes to open up generic markets faster. None of these
solutions, however, have garnered sufficient popular or governmental
support to be a realistic possibility. A uniform federal policy allowing
importation, on the other hand, would provide for efficient regulation
and unprecedented access to already available prescription drugs.
Rather than directly controlling prices through a board, allowing
competition through imports could indirectly drive down price by
putting pressure on U.S. pharmaceutical companies. With lower prices
and increased access, there could be an efficient allocation of
prescription drugs to U.S. citizens needing treatment.133
At this time, the FDA is too cautious and makes it too difficult
for people to get the medicines they want or need. FDA deterrence
effectively functions as a large transaction cost to importing drugs and
discourages an efficient market and maximum benefit to consumers.
As mentioned in Part II.B, the FDA’s concern for safety is likely
overstated and can largely be ameliorated by limiting accepted drug
importation to other developed countries with a similar regulatory
standard as the United States.134 Moreover, the government allowing

one of the happy incidents of the federal system that a single courageous state may,
if its citizens choose, serve as a laboratory; and try novel social and economic
experiments without risk to the rest of the country. . . . If we would guide by the
light of reason, we must let our minds be bold.”).
133
With a lowered price and increased demand, might this create a shortage?
While this is possible, especially for countries like Canada where the United States
could bleed the supply, it would likely adjust in time. If more markets open their
supply, potential shortage could be negated.
134
See Part II.B, supra note 95–103.
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importation of cheaper drugs would not significantly harm incentives
for pharmaceutical innovation.135
As such, the solution to pricing and access can be solved, on a
federal level, in one of two ways that this Article proposes: (1) an
expanded, codified personal use exemption, and (2) permitted
importation of prescription drugs from similarly regulated foreign
countries. Both of these proposals could include provisions writing
out patent infringement in cases where the drug would otherwise be
properly sold abroad.136 Moreover, legislation could list certain
essential, non-addictive pharmaceuticals—like heartburn treatment,
blood thinners, or cholesterol medicine—that may be deemed not to
pose a “significant health risk.” This may also exclude highly
scheduled controlled substances and other narcotics that are often
subject to abuse.
Recent bills have been submitted to Congress in continued
attempts to resolve this importation issue. While none have received
majority support for enactment, the bills include some interesting
proposals that deserve a closer look.137 The Pharmaceutical Market
Access and Drug Safety Act of 2011 (PMADSA) proposes the
designation of qualifying countries and drugs to be allowed for
importation.138 It also, like my proposals, would limit patent
infringement where drugs would have been properly sold abroad and
would establish a regulatory framework for Internet vendors.139
Likewise, the Personal Drug Importation Fairness Act of 2013
(PDIFA) proposes an extension of the personal use exemption based
135

See Part II.B.2, supra note 106–111.
See Pharmaceutical Market Access and Drug Safety Act of 2011, S. 319,
112th
Cong.
(2011),
https://www.govtrack.us/congress/bills/112/s319#summary/libraryofcongress
(denoting exception for when “resale in the United States of prescription drugs that
were properly sold abroad” as not constituting patent infringement). Recognizing
the patent implications of an import proposal, and while this issue is pressing, it is
outside of the scope of this article. For a discussion of state regulators and patent
infringement issues, see Lipski, supra note 119.
137
S. 319; see also Personal Drug Importation Fairness Act of 2013, H.R. 3715,
113th Cong. (2013), available at https://www.congress.gov/bill/113thcongress/house-bill/3715 (listing proposed factors to permit importation of foreign
prescription drugs, including the “same active-ingredients” as an FDA approved
counterpart and coming from a “qualified country”).
138
S. 319.
139
S. 319.
136
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on similar active ingredients, strength, direct shipping, and origin
from a “qualified” country.140 With these suggestions in mind, it is
possible to see successful importation policy in action.
A. Expanded Personal Use Exemption
An expanded personal use exemption would remedy the
uncertainty inherent in the current model.141 As it currently stands,
personal use importers cannot be sure that their conduct will go
unpunished, and the FDA discretionary standards do not establish a
realistic chance for use of the exemption. Much like Maine’s
legislation, a reliable importation right under federal law would
provide an effective means to import drugs for personal use and
would lead to savings for United States consumers.142 Similar to the
PDIFA, it would also be important to allow the exemption to function
in more instances. This could include an exemption past having “no
domestic alternatives” as under the current framework, as well as a
codification that would provide importer reliance.143 To the extent that
an individual bearing their own cost for importation safety is
problematic, there may also be potential for the legislation to include
some method for the registration of international sellers and
pharmacists as well.144
B. Foreign Regulatory Quality
Another potential effective method for providing cheaper
prices and higher access to prescription drugs would be to permit
drugs from foreign countries with regulatory methods similar to the
United States. As described in Part II.B.1, the FDA is incorrect in its
assumption that it is the only agency capable of ensuring safety for
consumers. Rather countries with a similar quality control for drug
manufacturing and oversight (e.g., a sufficiently acceptable regulatory
body overseeing operations) should be included for potential

140

H.R. 3715.
Reichertz & Friend, supra note 41, at 493.
142
Sterrett, supra note 128.
143
See supra note 44 and accompanying text.
144
S.P. 60, L.D. 171 126th Leg., 1st Reg. Sess. (Me. 2013).
141
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importation of these goods.145 How far the geographical limitations
should extend (e.g., which countries meet the level of being
“qualified”)146 is unclear. What is clear, though, is the need for an
expansion of this rule to allow for efficient pricing and access to
useful medications. Moreover, Maine’s success with a similar
expansion to Canadian and European pharmacies suggests a reliable
policy that would be conceivable without risking major safety
concerns. Such a policy may also include a list of acceptable
pharmaceuticals or qualifying substances through matching active
ingredients.147
Two questions arise, however, with regard to this type of
solution: (1) would this be a personal use or bulk importation basis?
(2) might it include foreign importation or, alternatively, only
domestic reimportation? On the first issue of importation amount, the
legislation in Maine, on the one hand, only permits such importation
from certain countries for “personal use.”148 I would argue, however,
that suitable regulatory oversight and funneling of these medications
through the proper channels in cooperating countries should negate
concerns for importing larger amounts of these medications from
foreign countries. Similarly, with regard to importing foreign drugs
versus reimporting domestically produced drugs, proper foreign
oversight could potentially disavow the need to limit policy to merely
a reimportation of domestically manufactured prescription drugs.149
V.

CONCLUSION

In conclusion, this Article proposes two potential,
nonexclusive solutions to progress prescription drug importation
policy in the United States and bridge the regulation gap that currently
exists today. These solutions could set up an efficient, cost-effective
145

Id.; see also H.R. 3715.
See e.g., H.R. 3715 (designating “qualified” countries generally without
providing specific guidelines for designation). But see supra note 95 (denoting
countries with “extremely low” instances of counterfeit or misleading medication at
1%). Perhaps these same countries could serve as a baseline for opening
importation.
147
H.R. 3715 (listing use of the “same active ingredient” as one factor in
permissible drug importation).
148
S.P. 60.
149
See infra note 94 and accompanying text.
146
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market for prescription drugs, while simultaneously solving the
problem of access to medications due to price. It seems important, if
not necessary, in our increasingly globalized world to expand this
commercial interchange between countries. Even larger—yet
immeasurable—potential benefits past monetary savings may later
manifest as well, such as increased access to effective medication
affecting overall healthcare or commercial interchange bringing up
prescription drug quality standards in more countries worldwide.

